Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06237101
Other study ID # OAIC: 1345/23
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 1, 2024
Est. completion date December 31, 2024

Study information

Verified date January 2024
Source University of Chile
Contact Antonello Penna, MD, PhD
Phone +56229788209
Email apenna@uchile.cl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to determine whether remifentanil has a facilitating effect on the generation of burst suppression by propofol in adult patients (18-60 years) candidates for elective surgery who require remifentanil and American Society of Anesthesiology (ASA) classification I or II. The main question it aims to answer are: • To determine whether remifentanil has a facilitating effect on the generation of burst suppression by propofol. Participants will undergo general anesthesia with remifentanil and propofol sequentially. After loss of consciousness, remifentanil will be adjusted to a medium or high concentration randomly and it will be determined at what concentration of propofol the burst suppressions are generated. Then, the concentrations of propofol that generate burst suppression associated with either a medium or high concentration of remifentanil will be compared.


Description:

Subjects will enter the ward, after which an 18 G intravenous cannula will be installed and will be monitored under the routinely applied ASA standard. Frontal EEG activity will be recorded using an anesthetic depth monitor and a baseline EEG will be recorded for 120 seconds with eyes closed. Subjects will then be preoxygenated. Once the oxygen concentration at the end of expiration reaches 90%, the administration of remifentanil will begin, under the Minto pharmacological model, to reach an effect site concentration of 7.5 ng/mL. Once the remifentanil concentration is reached, the infusion of propofol will begin at a rate of 15 mg/kg/h using Base Primea Orchestra, until loss of consciousness (LOC) is achieved. LOC will be defined as loss of response to verbal and tactile stimulation, which will be corroborated every 30 seconds. After this, the propofol infusion will be maintained at the concentration at which the LOC occurred, based on Marsh's pharmacological model, and rocuronium 0.6 mg/kg will be administered to facilitate orotracheal intubation. Once the patient has been intubated, the remifentanil will be lowered to a concentration of 4 ng/mL and the surgery will continue. After 5 min after the LOC occurred, according to randomization, the concentration of remifentanil will remain at 4 ng/mL or increase to 7.5 ng/mL, and 10 min after the LOC occurred the propofol infusion rate will be changed to 15 mg/kg/h for 10 min. After this, the propofol concentration at which the LOC occurred will be returned and remifentanil will be maintained at 4 ng/mL. After 5 min after completing the previous step, remifentanil will be increased to 7.5 ng/mL or maintained at 4 ng/mL in the opposite way to what happened previously. After 10 min after completing the previous step, propofol will be dosed again at a fixed rate of 15 mg/kg/h for 10 min. Finally, after this time has elapsed, the concentration of propofol at which the LOC occurred will be returned and the remifentanil will be dosed according to the surgical requirements. Throughout the protocol, hemodynamics will be maintained with the usual management of drugs such as ephedrine in boluses or norepinephrine in continuous infusion.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date December 31, 2024
Est. primary completion date August 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - American Society of Anesthesiology I or II - Elective surgery of low or intermediate risk Exclusion Criteria: - Neurological disease - Psychiatric disease - Use of psychoactive drugs or opioids - Altered basal state of consciousness - Allergy to propofol - Body mass index > 35 kg/m2 - Pre-existing renal, cardiac and/or hepatic dysfunction - Patient's refusal to participate

Study Design


Intervention

Drug:
High dose of remifentanil
The dose of remifentanil will be changed to determine the concentration of propofol at which burst suppressions are generated
Medium dose of remifentanil
The dose of remifentanil will be changed to determine the concentration of propofol at which burst suppressions are generated

Locations

Country Name City State
Chile Centro de Investigación Cínica Avanzada (CICA), Hospital Clinico de la Universidad de Chile Santiago RM
Chile Hospital Clinico de la Universidad de Chile Santiago RM

Sponsors (1)

Lead Sponsor Collaborator
University of Chile

Country where clinical trial is conducted

Chile, 

Outcome

Type Measure Description Time frame Safety issue
Primary Propofol estimated concentration by Marsh pharmacological model, which generates burst suppression [mcg/mL] During 10 minutes when propofol dosification is increased to 15 mg/kg/h
Secondary Propofol estimated concentration by Marsh pharmacological model, which generates loss of consciousness [mcg/mL] Minutes, during anesthesia induction is performed
Secondary Mean arterial pressure during burst suppression mmHg During 10 minutes when propofol dosification is increased to 15 mg/kg/h
Secondary Total ephedrine dose mg During all protocol, 40 min
Secondary Maximal dose of norepinephrine mcg/kg/min During all protocol, 40 min
Secondary Bispectral index at burst suppression (0-100), 0 indicates a flat electroencephalogram and 100 indicates to be awake. During 10 minutes when propofol dosification is increased to 15 mg/kg/h
See also
  Status Clinical Trial Phase
Completed NCT04562181 - Consistency Evaluation of the qCON, qNOX Indices and Bispectral Index N/A
Recruiting NCT05487768 - Functional Connectivity After Anterior Cruciate Ligament Reconstruction N/A
Active, not recruiting NCT06443827 - Effect of Intravenous Amantadine Sulphate on Disorders of Consciousness Phase 2
Completed NCT03685227 - A Closer Look at Yoga Nidra: Sleep Lab Analyses N/A
Active, not recruiting NCT04455295 - Testing the Noradrenergic Hypothesis of Transcutaneous Vagus Nerve Stimulation N/A
Completed NCT04665453 - Dexmedetomidine and Melatonin for Sleep Induction for EEG in Children N/A
Active, not recruiting NCT00988702 - Shaolin Dan Tian Breathing Fosters Relaxed and Attentive Mind Phase 1/Phase 2
Recruiting NCT06084455 - TMS-evoked Potentials During Aerobic Exercise N/A
Completed NCT03330236 - EEG - Guided Anesthetic Care and Postoperative Delirium N/A
Recruiting NCT05533567 - Electroencephalographic Profiles During General Anesthesia: a Comparative Study of Remimazolam and Propofol N/A
Completed NCT05566444 - TMS-evoked Potentials During Heat Pain N/A
Completed NCT05184686 - Effects of Electromagnetic Field and Noise on Resting Electroencephalogram of Health Subjects N/A
Completed NCT00639548 - ERPS, BIS and Entropy for Neuromonitoring in ICU Patients N/A
Recruiting NCT03745963 - The Influence of Skin-to-skin Contact on Cortical Activity During Painful Procedures on Preterm Infants in the NICU Phase 3
Completed NCT04050384 - Effect of a Vibratory Stimulus on Mitigating Nociception-specific Responses to Skin Puncture in Neonates N/A
Recruiting NCT03801785 - Efficacy of Non-Nutritive Sucking (NNS) on Balance and Gait Measured in 12-42 Month-Old Healthy Children Over 36 Months N/A
Recruiting NCT03362775 - EEG Analysis During Light Propofol Sedation Phase 1
Completed NCT04472247 - Sedation Monitoring Using Frontal Electroencephalogram, Electromyogram and Hemodynamic Responses to Pain in Critical Care
Completed NCT03152331 - Nurse and Physician Stress Reduction: Learning Receptive Awareness Via EEG Feedback N/A
Completed NCT04884893 - Effect of Nitrous Oxide on EEG Phase 1